Rationale and clinical status of 41.8°C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2891-2894

  Robins, H I ^a   D'Oleire, F ^a   Grosen, E ^a   Spriggs, D ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Malignant melanoma; Melphalan; Tumor necrosis factor; Whole body hyperthermia

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR;

BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERTHERMIA; MELANOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; MELPHALAN; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030800675     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)